Trial Profile
A Retrospective Study Assessing the Efficacy and Safety of Cabazitaxel (CABA) Rechallenge in Heavily-Treated Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Jul 2017
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 02 Jul 2017 New trial record
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.